These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16601163)

  • 1. Medicine. Old drug, new hope for Marfan syndrome.
    Travis J
    Science; 2006 Apr; 312(5770):36-7. PubMed ID: 16601163
    [No Abstract]   [Full Text] [Related]  

  • 2. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.
    Habashi JP; Judge DP; Holm TM; Cohn RD; Loeys BL; Cooper TK; Myers L; Klein EC; Liu G; Calvi C; Podowski M; Neptune ER; Halushka MK; Bedja D; Gabrielson K; Rifkin DB; Carta L; Ramirez F; Huso DL; Dietz HC
    Science; 2006 Apr; 312(5770):117-21. PubMed ID: 16601194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
    Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II blockade in Marfan's syndrome.
    van Dijk FS; Meijers-Heijboer H; Pals G
    N Engl J Med; 2008 Oct; 359(16):1733; author reply 1733-4. PubMed ID: 18927954
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug shows promise for marfan syndrome.
    Kuehn BM
    JAMA; 2006 May; 295(17):1990. PubMed ID: 16670402
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin II blockade in Marfan's syndrome.
    Jiménez SA; Rosenbloom J
    N Engl J Med; 2008 Oct; 359(16):1732-3; author reply 1733-4. PubMed ID: 18927953
    [No Abstract]   [Full Text] [Related]  

  • 7. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
    Cook JR; Clayton NP; Carta L; Galatioto J; Chiu E; Smaldone S; Nelson CA; Cheng SH; Wentworth BM; Ramirez F
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):911-7. PubMed ID: 25614286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Novel pharmacological strategies for aortic dilation in Marfan syndrome: from mouse models to human patients].
    Perrino C; Schiattarella GG; Bottino R; Magliulo F; Oliveti M; Esposito G; Trimarco B
    G Ital Cardiol (Rome); 2014; 15(7-8):408-17. PubMed ID: 25174594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicine. Frightening risk of Marfan syndrome, and potential treatment, elucidated.
    Couzin-Frankel J
    Science; 2011 Apr; 332(6027):297. PubMed ID: 21493836
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting TGF-beta and the extracellular matrix in Marfan's syndrome.
    Kalluri R; Han Y
    Dev Cell; 2008 Jul; 15(1):1-2. PubMed ID: 18606132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-29b participates in early aneurysm development in Marfan syndrome.
    Merk DR; Chin JT; Dake BA; Maegdefessel L; Miller MO; Kimura N; Tsao PS; Iosef C; Berry GJ; Mohr FW; Spin JM; Alvira CM; Robbins RC; Fischbein MP
    Circ Res; 2012 Jan; 110(2):312-24. PubMed ID: 22116819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome.
    Yang HH; Kim JM; Chum E; van Breemen C; Chung AW
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):305-312.e2. PubMed ID: 20189193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?
    Mallat Z; Daugherty A
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):e10-2. PubMed ID: 25550201
    [No Abstract]   [Full Text] [Related]  

  • 14. Paternal fibrillin-1 mutation transmitted to an affected son with neonatal marfan syndrome: the importance of early recognition.
    Elshershari H; Harris C
    Cardiol Young; 2014 Aug; 24(4):735-8. PubMed ID: 23930893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atenolol versus Losartan in Marfan's Syndrome.
    Mallat Z; Tedgui A
    N Engl J Med; 2015 Mar; 372(10):980. PubMed ID: 25738683
    [No Abstract]   [Full Text] [Related]  

  • 16. Atenolol versus Losartan in Marfan's Syndrome.
    Lacro RV; Dietz HC; Mahony L
    N Engl J Med; 2015 Mar; 372(10):980-1. PubMed ID: 25738680
    [No Abstract]   [Full Text] [Related]  

  • 17. Atenolol versus Losartan in Marfan's Syndrome.
    Treasure T; Pepper J; Mohiaddin R
    N Engl J Med; 2015 Mar; 372(10):978-9. PubMed ID: 25738682
    [No Abstract]   [Full Text] [Related]  

  • 18. Atenolol versus Losartan in Marfan's Syndrome.
    Ziganshin BA; Mukherjee SK; Elefteriades JA
    N Engl J Med; 2015 Mar; 372(10):977-8. PubMed ID: 25738681
    [No Abstract]   [Full Text] [Related]  

  • 19. Of Marfan's syndrome, mice, and medications.
    Bowen JM; Connolly HM
    N Engl J Med; 2014 Nov; 371(22):2127-8. PubMed ID: 25405389
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of losartan in prevention of aortic dilatation in Marfan syndrome: A systematic review and meta-analysis.
    Li L; Yamani N; Al-Naimat S; Khurshid A; Usman MS
    Eur J Prev Cardiol; 2020 Sep; 27(13):1447-1450. PubMed ID: 31260329
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.